About Jeito

Jeito Capital is a leading global investment company. Jeito was founded and directed by Dr. Rafaèle Tordjman, a hematologist and former fellow in Paris University Hospitals and research scientist at INSERM, who has been an investor in life sciences for more than 20 years.

Jeito has 1.6bn euros of assets under management

Jeito Capital has implemented a patient benefit driven approach that finances and accelerates cutting-edge medical innovation. Jeito supports and accompanies entrepreneurs through its multidisciplinary team of experts across the entire drug value chain, as well as through a significant capital contribution to ensure the growth of companies. Jeito thus contributes to the emergence of leaders in specific therapeutic areas and accelerates the commercialization of innovative treatments throughout the world, particularly in Europe and the United States, for the benefit of patients.

Jeito Capital has built a solid and diverse portfolio of Biopharma companies, primarily European. Jeito has invested in therapeutic areas of high unmet medical need, notably : oncology, autoimmune and inflammatory, ophthalmology, cardiology, obesity, reproductive medicine and women’s health, neuromuscular, neurodegenerative and cardio-metabolic diseases.